French Early Access Programs
Autorisation d’accès compassionnel (AAC) – General Guide
France’s Early Access Programs (EAP) provide a critical pathway for patients with serious and rare diseases to access innovative treatments before they are fully authorized on the market.
Through programs like the Early Access Authorization (AAP) and Compassionate Access Authorization (AAC or CPC), patients in urgent need can benefit from breakthrough therapies earlier.
This guide explains these programs in detail, helping you navigate France’s unique early access landscape.
Temporary Authorization for Use vs Early Access Programs
Understanding key terminology
In the context of French early access, terminology plays a crucial role in understanding the available pathways. Below are the key terms youʼll encounter, each reflecting a distinct process or program:
- Early Access Program (EAP) : A broad framework allowing access to investigational drugs for patients with unmet medical needs.
- Autorisation d’Accès Précoce (AAP): The current formal term for early access to innovative treatments, replacing the older Temporary Authorization for Use (ATU) framework.
- Temporary Authorization for Use (ATU): A now-phased-out term, largely replaced by AAP in 2021.
- Autorisation d’Accès Compassionnel (AAC): The compassionate access route, for a specific patient needing a drug that meets a therapeutic gap.
- Cadre de prescription compassionnelle (CPC) : 3-year Programs designed by ANSM for specific drug / identified unmet medical need.
Understanding which specific program or authorization is relevant to securing Early Access for your treatment. AzurBio helps pharmaceutical companies select the right path, navigating the regulatory details that come with each option.
Types of Early Access Available
Early Access Authorization (AAP)
The Autorisation d’Accès Précoce (AAP) is intended for innovative treatments addressing serious diseases where no alternative treatment exists.
This program provides an expedited route to introduce groundbreaking drugs to patients in critical need.
Eligibility: The drug must be innovative, aimed at serious diseases, fulfills an unmet medical need and the implementation of the treatment cannot be postponed.
Process: After receiving an opinion from ANSM, applications are submitted electronically to HAS.
Timeline: The evaluation period typically lasts up to 90 days, making it a fast-tracked option for patient access.
Compassionate Access Authorization (AAC)
The Autorisation d’Accès Compassionnel (AAC) is aimed for one specific patient due to a lack of suitable alternatives on French market.
Eligibility: The drug does not have a marketing authorization in France, is aimed at serious diseases, fulfills an unmet medical need and the implementation of the treatment cannot be postponed.
NB : the laboratory has undertaken to file an application for early access authorization.
Process: The application is made for one patient to ANSM by a healthcare professional via a specific platform named e-saturne.
Timeline: can be very fast
Application Process for Early Access
The application process for AAP follows a structured pathway, designed to ensure that patient safety is prioritized while addressing unmet medical needs:
Preparation: A comprehensive dossier is prepared, detailing the drug’s efficacy, safety, and justifications for unmet medical need. This includes all clinical data and documentation.
Submission: Applications are submitted to HAS after obtaining a positive opinion from ANSM.
Evaluation: Once submitted, the regulatory bodies review the application and may request further information. The standard evaluation timeline is around 90 days.
Post-Approval Monitoring: Upon approval, the drug is available under early access. However, continuous monitoring and safety reporting are mandatory throughout the program duration.
How AzurBio Streamlines the Process
At AzurBio, we simplify the entire application process by taking care of:
Document Preparation: We handle the technical details of the dossier, ensuring that all regulatory requirements are met.
Communication with Authorities: Our strong ties with key authorities, such as ANSM and HAS, ensure smoother and more efficient communication, reducing delays.
Ongoing Support: Once approved, we can manage patient inclusion, safety monitoring, and periodic reporting, ensuring compliance with French regulations throughout the early access period.
Challenges of Early Access
1. Mandatory set-up of an Exploitant structure
In France, having an Exploitant structure is mandatory to run early access programs because it ensures that the entity responsible for the medicinal product is established within the country and complies with national regulations. The exploitant is accountable for the distribution, monitoring, and pharmacovigilance of the product, which are critical components for patient safety in early access scenarios.
2. Early High-Risk Commitment
Entering the French market under early access involves significant upfront commitment without the certainty of market success. The regulatory process is demanding, and the need to set up an Exploitant structure adds further pressure.
3. Regulatory Hurdles
Navigating the French regulatory landscape requires local expertise and a deep understanding of the market. From managing relationships with ANSM and HAS to ensuring full compliance with French regulations, the process can be very complex.
4. Complex Hiring Process
Establishing a local entity in France, as required by the Exploitant structure, demands local recruitment and expertise. Hiring local staff – particularly specialists familiar with the intricate regulatory processes – can be a lengthy and resource-intensive endeavor, delaying your ability to start operations.
5. Resource Demands
Setting up an Exploitant structure and meeting regulatory requirements in France demands significant resource allocation, both in terms of time and personnel. It is a challenge that can delay product availability and market entry.
Overcoming Challenges with AzurBio
Bypassing the 18-Month Timeline
Setting up a compliant local subsidiary in France can take up to 18 months, delaying your product’s market entry. AzurBio offers an immediate solution by providing a ready-to-operate Exploitant service, allowing you to bypass this lengthy timeline.
This means you can launch your Early Access Program without the delay of building a local entity, ensuring that your product reaches patients faster and in full compliance with French regulations.
Regulatory Expertise
With AzurBioʼs extensive experience, you don’t need to navigate regulatory hurdles alone.
We manage every step of the application and approval process, handling communication with health authorities and ensuring compliance from the outset.
Mitigating high-risk commitment
AzurBio offers ready-to-use Exploitant services, so you do not need to create your own subsidiary immediately. Instead of establishing a full local structure from the start, you can leverage AzurBioʼs pre-established, compliant subsidiary to manage your product launch and regulatory obligations.
When you’re ready and feel confident in the market, you have the option to acquire this subsidiary, allowing a smooth transition to full control without the high upfront risk and costs. This approach lets you focus on your product’s success while we handle operational complexities such as day-to-day management, compliance, and patient monitoring.
Simplifying the Hiring Process
With AzurBio, you avoid the complexities of early local recruitment. Instead of setting up a full local team, AzurBio offers a pre-existing Exploitant service, allowing you to meet regulatory requirements without the need for immediate local hiring.
As your product gains traction, you can gradually transition to your own local staff at your pace, while AzurBio manages the operational and regulatory responsibilities during the early stages.
Pharmacovigilance and Data Collection
Once a product is granted early access, itʼs subject to ongoing pharmacovigilance and data collection.
This involves continuous monitoring of drug safety and efficacy, with mandatory adverse event reporting to ensure that the drug remains safe for patient use.
AzurBio provides comprehensive pharmacovigilance services, managing safety monitoring and data reporting on your behalf, ensuring full compliance with French and European regulatory standards.
Interested in fast-tracking your product entry into France’s Early Access Programs ?
Contact AzurBio today to schedule a personalized consultation and explore how we can help you navigate the regulatory landscape and bring your innovative treatments to patients sooner.